Three dimensional cultivation increases chemo- and radioresistance of colorectal cancer cell lines.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 08 07 2020
accepted: 10 12 2020
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 24 4 2021
Statut: epublish

Résumé

Although 2D cell cultures are commonly used to predict therapy response, it has become clear that 3D cultures may better mimic the in vivo situation and offer the possibility of tailoring translational clinical approaches. Here, we compared the response of 2D and 3D colorectal cancer (CRC) cell lines to irradiation and chemotherapy. Classic 2D cultures and 3D spheroids of CRC cell lines (CaCo2, Colo205, HCT116, SW480) were thoroughly established, then irradiated with doses of 1, 4, or 10 Gy, using a clinical-grade linear accelerator. The response was assessed by immunohistochemistry, flow cytometry, and TUNEL assays. Upon irradiation, CRC 3D spheroids were morphologically altered. After irradiation with 10 Gy, annexin V/PI staining revealed a 1.8- to 4-fold increase in the apoptosis rate in the 2D cell cultures (95% CI 3.24±0.96), and a 1.5- to 2.4-fold increase in the 3D spheroids (95% CI 1.56±0.41). Irradiation with 1 Gy caused 3- and 4-fold increases in TUNEL positive cells in the CaCo2 and HCT116 (p = 0.01) 2D cultures, respectively, compared with a 2-fold increase in the 3D spheroids. Furthermore, the 2D and 3D cultures responded differently to chemotherapy; the 3D cultures were more resistant to 5-FU and cisplatin, but not to doxorubicin and mitomycin C, than the 2D cultures. Taken together, CRC cells cultured as 3D spheroids displayed markedly higher resistance to irradiation therapy and selected chemotherapeutic drugs than 2D cultures. This in vitro difference must be considered in future approaches for determining the ideal in vitro systems that mimic human disease.

Identifiants

pubmed: 33395433
doi: 10.1371/journal.pone.0244513
pii: PONE-D-20-21145
pmc: PMC7781370
doi:

Substances chimiques

Antineoplastic Agents 0
Doxorubicin 80168379AG
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244513

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
BMC Genomics. 2008 Feb 26;9:99
pubmed: 18302766
Radiat Oncol. 2017 Jan 13;12(1):16
pubmed: 28086989
Oncotarget. 2016 Jul 19;7(29):45745-45756
pubmed: 27304190
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Cancer. 2015 Jun 15;136(12):2949-60
pubmed: 25408479
J Transl Med. 2012 Mar 06;10:38
pubmed: 22394685
Int J Mol Sci. 2018 Aug 30;19(9):
pubmed: 30200215
Sci Rep. 2020 Jul 6;10(1):11071
pubmed: 32632214
Clin Cancer Res. 2002 May;8(5):1148-54
pubmed: 12006531
Strahlenther Onkol. 2011 Apr;187(4):225-30
pubmed: 21424305
Oncol Rep. 2015 Apr;33(4):1837-43
pubmed: 25634491
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Mol Carcinog. 2007 Oct;46(10):872-85
pubmed: 17455221
Cell Stem Cell. 2020 Jan 2;26(1):17-26.e6
pubmed: 31761724
Cancer Cell Int. 2019 Jan 14;19:16
pubmed: 30651721
Int J Dev Biol. 2006;50(7):645-52
pubmed: 16892178
World J Surg. 1992 Sep-Oct;16(5):848-57
pubmed: 1462619
Biomed Opt Express. 2017 Feb 28;8(3):1911-1925
pubmed: 28663873
J Control Release. 2012 Dec 10;164(2):192-204
pubmed: 22613880
Nat Med. 2019 Oct;25(10):1607-1614
pubmed: 31591597
Biotechnol Adv. 2014 Nov 15;32(7):1256-1268
pubmed: 25116894
Int J Cancer. 2009 Nov 15;125(10):2450-5
pubmed: 19670329
World J Gastroenterol. 2019 Sep 7;25(33):4850-4869
pubmed: 31543678
J Clin Oncol. 2005 Aug 20;23(24):5644-50
pubmed: 16110023
Oncol Lett. 2018 Mar;15(3):3008-3016
pubmed: 29435031

Auteurs

Jana Koch (J)

Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
University of Tübingen, Tübingen, Germany.

Dina Mönch (D)

Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
University of Tübingen, Tübingen, Germany.

Annika Maaß (A)

Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
University of Tübingen, Tübingen, Germany.

Christian Gromoll (C)

Department of Radiation Therapy, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Department of Radiation Therapy, Marienhospital, Stuttgart, Germany.
University of Stuttgart, Stuttgart, Germany.

Thomas Hehr (T)

Department of Radiation Therapy, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Department of Radiation Therapy, Marienhospital, Stuttgart, Germany.

Tobias Leibold (T)

Department of General and Visceral Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Hans J Schlitt (HJ)

University Medical Centre Regensburg, Regensburg, Germany.

Marc-H Dahlke (MH)

Department of General and Visceral Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Philipp Renner (P)

Department of General and Visceral Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
University Medical Centre Regensburg, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH